AsciepiX Therapeutics Inc., has announced the receipt of $35 million Series A financing led by Perceptive Xontogeny Venture Fund. The proceeds of the funding will… Read More »AsciepiX Therapeutics Inc., (New Jersey, US) has announced a $35M investment to be used for the treatment of retinal diseases through Phase 1/2a clinical trials
Clinical researchers at the Department of Ophthalmology, St. Joseph’s Hospital, London, Ontario have reported that a systematic review and meta-analysis between pars plana vitrectomy to… Read More »A systematic review and meta-analysis has reported outcomes for ocriplasmin treatment and surgery (PPV) for macular hole closure.
Researchers in the Institute of Molecular and Clinical Ophthalmology Basel, Switzerland have reported a novel strategy to use near-infrared (NIR) wavelength inputs to restore blind… Read More »Innovative approach aims to use near-infrared to convert light into heat through an engineered channel to restore retina sensitivity
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the August 7th, 2020 edition of EURETINA’s web-based digital magazine,… Read More »August 7th, 2020: “EURETINA-Brief”© Issue No. 218
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the December 18th, 2019 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »December 18th, 2019: “EURETINA-Brief”© Issue No. 204
Genetics and Genomics of Eye Disease, 1st Edition – Advancing to Precision Medicine (Elsevier) Editors: Xiaoyi Gao Paperback ISBN: 9780128162224 eBook ISBN: 9780128167274; Pages 383,… Read More »Genetics and Genomics of Eye Disease, 1st Edition – Advancing to Precision Medicine (Elsevier) Editors: Xiaoyi Gao Ph.D.
Researchers at the Sydney Institute of Vision Science, in New South Wales, Australia report that good long-term efficacy of anti-VEGF therapy over 5 years provides… Read More »Five-year outcomes of retinal vein occlusion provide long term data for anti-VEGF treatments on real-world data
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the April 16th, 2019 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »April 16th, 2019: “EURETINA-Brief” Issue No. 190
Editas Medicine, Inc. (NASDAQ: EDIT), based in Dublin, Ireland and Cambridge, Massachusetts, and Allergan plc (NYSE: AGN), also headquartered in Dublin, Ireland have announced the… Read More »Editas Medicine Inc. (NASDAQ:EDIT), and Allergan plc (NYSE:AGN), progress option rights to develop CRISPR technology for treatment of LCA 10
EURETINA, through a collaboration with Fight for Sight, have announced a dedicated Research Call to support clinical research in the field of sub-macular haemorrhage (SMH),… Read More »***EURETINA / Fight for Sight launch Sub-Macular Haemorrhage (SMH) Clinical Research Call***